EGFR and non-small cell lung carcinoma: Previous studies have indicated that the concomitant use of EGFR inhibitors and KRAS inhibitors can yield clinical benefits in the treatment of non-small cell lung cancer (NSCLC) and colorectal cancer (Gregorc et al., 2024; Zhou et al., 2023; Yaeger et al., 2023).